Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

[1]  D. Vorchheimer.  What is QT interval prolongation? , 2005, The Journal of family practice.

[2]  J. Mendelson,et al.  Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers , 1996, Psychopharmacology.

[3]  U. Ravens,et al.  Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for “reverse use dependent” block , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  A. Camm,et al.  Acute electrophysiologic effects of an HT2-serotonin antagonist, ketanserin, in humans , 1990, Cardiovascular Drugs and Therapy.

[5]  J. W. Atkinson,et al.  Cardiac arrhythmias. , 2005, Respiratory care clinics of North America.

[6]  P. Dorian,et al.  Azimilide Decreases Defibrillation Voltage Requirements and Increases Spatial Organization During Ventricular Fibrillation , 1999, Journal of Interventional Cardiac Electrophysiology.

[7]  A. Mallet,et al.  Pharmacokinetic Analysis of Mizolastine in Healthy Young Volunteers After Single Oral and Intravenous Doses: Noncompartmental Approach and Compartmental Modeling , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  R. Bergstrand,et al.  Assessment of frequency dependency of the class III effects of almokalant: A study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals , 1996, Cardiovascular Drugs and Therapy.

[9]  L. Bergfeldt,et al.  “Normal” response of the QT interval and QT dispersion following intravenous injection of the sodium channel blocker disopyramide: Methodological aspects , 1995, Cardiovascular Drugs and Therapy.

[10]  M. Arita,et al.  Effects of cibenzoline, a new class Ia antiarrhythmic drug, on various membrane ionic currents and action potentials of guinea-pig ventricular cells , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[11]  B. Davies,et al.  The effect of tricyclic antidepressant drugs on the heart , 1976, Archives of Toxicology.

[12]  Panagiotis Korantzopoulos,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[13]  L. Barbara,et al.  The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis , 2004, European Journal of Clinical Pharmacology.

[14]  D. Stott,et al.  Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval , 2004, European Journal of Clinical Pharmacology.

[15]  J. Hancox,et al.  Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine , 2002, British journal of pharmacology.

[16]  Jun Zhou,et al.  Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. , 2002, The Journal of pharmacology and experimental therapeutics.

[17]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[18]  R. Shah.  Drug‐induced prolongation of the QT interval: why the regulatory concern? , 2002, Fundamental & clinical pharmacology.

[19]  R. Shah.  Drug‐induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity , 2002, Fundamental & clinical pharmacology.

[20]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[21]  Dierk Thomas,et al.  The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. , 2002, The Journal of pharmacology and experimental therapeutics.

[22]  D. Hoban,et al.  A Critical Review of the Fluoroquinolones , 2002, Drugs.

[23]  W. Catterall,et al.  The IUPHAR compendium of voltage-gated ion channels , 2002 .

[24]  Maurizio Recanatini,et al.  Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes , 2002, Drug safety.

[25]  Derek Leishman,et al.  Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. , 2002, Current opinion in drug discovery & development.

[26]  B. Lüderitz,et al.  [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects]. , 2001, Deutsche medizinische Wochenschrift.

[27]  J. Prichard,et al.  Torsades de Pointes Associated with High Dose Levomethadyl Acetate (ORLAAM®) , 2001, Journal of Addictive Diseases.

[28]  R. Frothingham,et al.  Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin , 2001, Pharmacotherapy.

[29]  J L Puglisi,et al.  LabHEART: an interactive computer model of rabbit ventricular myocyte ion channels and Ca transport. , 2001, American journal of physiology. Cell physiology.

[30]  D. Roden,et al.  Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias , 2001, Journal of cardiovascular pharmacology.

[31]  M. Vos,et al.  Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias. , 2001, Pharmacology & therapeutics.

[32]  S. Connolly,et al.  Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. , 2001, The American journal of cardiology.

[33]  A H Glassman,et al.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.

[34]  S. Gläser,et al.  Torsades de pointes caused by Mibefradil , 2001, European journal of heart failure.

[35]  Jiesheng Kang,et al.  Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. , 2001, The Journal of pharmacology and experimental therapeutics.

[36]  W. Grimm,et al.  Doxepin-induced torsade de pointes tachycardia. , 2001, Annals of internal medicine.

[37]  C. Antzelevitch.  Heterogeneity of cellular repolarization in LQTS: the role of M cells , 2001 .

[38]  L. Carlsson.  Drug-induced torsade de pointes: the perspectives of industry , 2001 .

[39]  B. Darpö,et al.  Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes , 2001 .

[40]  M. Barecki,et al.  In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[41]  B. Drolet,et al.  Pimozide (Orap®) Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current in Native Cardiac Myocytes , 2001, Journal of cardiovascular pharmacology and therapeutics.

[42]  I. Khan,et al.  Cocaine-induced torsades de pointes in idiopathic long Q-T syndrome. , 2001, American journal of therapeutics.

[43]  R. Stanford,et al.  Torsades de Pointes Associated with Chlorpromazine: Case Report and Review of Associated Ventricular Arrhythmias , 2001, Pharmacotherapy.

[44]  Elisabetta Poluzzi,et al.  Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus , 2001, European Journal of Clinical Pharmacology.

[45]  F. Azarbayjani,et al.  Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. , 2001, Current pharmaceutical design.

[46]  Gea-Ny Tseng,et al.  IKr: The hERG Channel , 2001 .

[47]  Hua-rong Lu,et al.  Female Gender is a Risk Factor for Drug‐Induced Long QT and Cardiac Arrhythmias in an In Vivo Rabbit Model , 2001, Journal of cardiovascular electrophysiology.

[48]  T J Campbell,et al.  HERG K+ channels: friend and foe. , 2001, Trends in pharmacological sciences.

[49]  D. Roden.  Pharmacogenetics and drug-induced arrhythmias. , 2001, Cardiovascular research.

[50]  G. Gintant,et al.  The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.

[51]  C. January,et al.  Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. , 2001, Molecular pharmacology.

[52]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[53]  Itsuo Kodama,et al.  Short- and Long-Term Effects of Amiodarone on the Two Components of Cardiac Delayed Rectifier K+ Current , 2001, Circulation.

[54]  J. Pezzullo,et al.  Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. , 2001, British journal of clinical pharmacology.

[55]  D. Abernethy,et al.  Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation , 2001, Clinical pharmacology and therapeutics.

[56]  W S Redfern,et al.  Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. , 2001, Cardiovascular research.

[57]  D. Roden,et al.  Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. , 2001, The Journal of pharmacology and experimental therapeutics.

[58]  B. Lund,et al.  Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial , 2001, Journal of clinical psychopharmacology.

[59]  L. Carlsson,et al.  Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potential. , 2001, Cardiovascular research.

[60]  D. Walker,et al.  Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[61]  S. Doggrell.  Tedisamil: master switch of nature? , 2001, Expert opinion on investigational drugs.

[62]  D. Roden,et al.  Sympathetic Activation Enhances QT Prolongation by Quinidine , 2001, Journal of cardiovascular electrophysiology.

[63]  G. Edwards,et al.  Potentiation of halofantrine‐induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine , 2001, British journal of pharmacology.

[64]  Hua-rong Lu,et al.  Species Plays an Important Role in Drug‐Induced Prolongation of Action Potential Duration and Early Afterdepolarizations in Isolated Purkinje Fibers , 2001, Journal of cardiovascular electrophysiology.

[65]  S. Priori,et al.  The Long QT Syndrome , 1997, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[66]  A J Camm,et al.  Evaluation of Drug-Induced QT Interval Prolongation , 2001, Drug safety.

[67]  D J Triggle,et al.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.

[68]  K. Hashimoto,et al.  Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. , 2000, Toxicology and applied pharmacology.

[69]  R. Falk,et al.  Dofetilide: a new pure class III antiarrhythmic agent. , 2000, American heart journal.

[70]  L. Annunziato,et al.  Inhibition of HERG1 K+ channels by the novel second‐generation antihistamine mizolastine , 2000, British journal of pharmacology.

[71]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[72]  O. Pongs,et al.  Effects of fluoroquinolones on HERG currents. , 2000, European journal of pharmacology.

[73]  A. Templeton,et al.  Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. , 2000, European journal of pharmacology.

[74]  B. Drolet,et al.  Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders , 2000, Circulation.

[75]  K. Hashimoto,et al.  QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring. , 2000, Journal of cardiovascular pharmacology.

[76]  L. Shuba,et al.  Differences in the effects of urinary incontinence agents S‐oxybutynin and terodiline on cardiac K+ currents and action potentials , 2000, British journal of pharmacology.

[77]  T F McDonald,et al.  Low-affinity block of cardiac K(+) currents by nifedipine. , 2000, European journal of pharmacology.

[78]  T J Campbell,et al.  Inhibition of HERG potassium channels by the antimalarial agent halofantrine , 2000, British journal of pharmacology.

[79]  A. Camm,et al.  The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.

[80]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[81]  H. R. Lu,et al.  Are there sex-specific differences in ventricular repolarization or in drug-induced early afterdepolarizations in isolated rabbit purkinje fibers? , 2000, Journal of cardiovascular pharmacology.

[82]  D. Fish,et al.  The safety profile of the fluoroquinolones. , 2000, Clinical therapeutics.

[83]  S. Kasper,et al.  Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance , 2000, International clinical psychopharmacology.

[84]  K. Zbuk,et al.  Quetiapine fumarate overdose: Clinical and pharmacokinetic lessons from extreme conditions , 2000, Clinical pharmacology and therapeutics.

[85]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[86]  P. Ball,et al.  Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. , 2000, The Journal of antimicrobial chemotherapy.

[87]  D. Flockhart,et al.  Greater quinidine‐induced QTc interval prolongation in women , 2000, Clinical pharmacology and therapeutics.

[88]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[89]  W. Ho,et al.  Blockade of the HERG human cardiac K+ channel by the antidepressant drug amitriptyline , 2000, British journal of pharmacology.

[90]  D. Rampe,et al.  High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. , 2000, European journal of pharmacology.

[91]  J. Clozel,et al.  Nonlinear kinetics and pharmacologic response to mibefradil , 2000, Clinical pharmacology and therapeutics.

[92]  M. Gralinski.  The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. , 2000, Journal of pharmacological and toxicological methods.

[93]  W. Lederer,et al.  K 1 currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin , 2022 .

[94]  H. Al-Khalidi,et al.  Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. , 2000 .

[95]  M. Diaz,et al.  Effects of mefloquine on cardiac contractility and electrical activity in vivo, in isolated cardiac preparations, and in single ventricular myocytes , 2000, British journal of pharmacology.

[96]  W. Maier,et al.  Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial , 2000 .

[97]  C. Vannier,et al.  The preclinical assessment of the risk for QT interval prolongation. , 2000, Therapie.

[98]  J. Barhanin,et al.  Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. , 2000, Therapie.

[99]  P. Ott.  Ventricular arrhythmias , 2000, Current treatment options in cardiovascular medicine.

[100]  W. Crumb,et al.  Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. , 2000, The Journal of pharmacology and experimental therapeutics.

[101]  Khan,et al.  Arachidonic acid metabolites alter G protein-mediated signal transduction in heart. Effects on muscarinic K+ channels , 1990, The Journal of general physiology.

[102]  C. January,et al.  Droperidol Lengthens Cardiac Repolarization due to Block of the Rapid Component of the Delayed Rectifier Potassium Current , 1999, Journal of cardiovascular electrophysiology.

[103]  M. Arita,et al.  Bepridil differentially inhibits two delayed rectifier K+ currents, IKr and IKs, in guinea‐pig ventricular myocytes , 1999, British journal of pharmacology.

[104]  S. Viskin.  Long QT syndromes and torsade de pointes , 1999, The Lancet.

[105]  S. Nattel,et al.  Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. , 1999, The American journal of cardiology.

[106]  F. Charpentier,et al.  Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. , 1999, Cardiovascular research.

[107]  T J Campbell,et al.  Inhibition of the human ether‐a‐go‐go‐related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states , 1999, British journal of pharmacology.

[108]  T. Ogura,et al.  Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline. , 1999, The Journal of pharmacology and experimental therapeutics.

[109]  T. Iga,et al.  Sustained QT prolongation induced by tacrolimus in guinea pigs. , 1999, Life sciences.

[110]  Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys. , 1999, European journal of pharmacology.

[111]  CHARLES ANTZELEVITCH,et al.  The M Cell: , 1999, Journal of cardiovascular electrophysiology.

[112]  K. Hashimoto,et al.  Effects of azimilide, a KV(r) and KV(s) blocker, on canine ventricular arrhythmia models. , 1999, European journal of pharmacology.

[113]  A. Moss,et al.  A review of the cardiac systemic side‐effects of antihistamines: ebastine , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[114]  G. Cheymol,et al.  Electrophysiological effects of cetirizine, astemizole and d‐sotalol in a canine model of long QT syndrome , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[115]  Cavero,et al.  QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.

[116]  G. Talbot,et al.  The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. , 1999, Clinical therapeutics.

[117]  A. Brown,et al.  Cardiovascular safety of fexofenadine HCl , 1999, Clinical and Experimental Allergy.

[118]  C. January,et al.  Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.

[119]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[120]  T J Campbell,et al.  Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate , 1999, British journal of pharmacology.

[121]  R. Trohman,et al.  Drug-induced torsade de pointes. , 1999, Circulation.

[122]  K. Eguchi,et al.  Clarithromycin associated with torsades de pointes. , 1999, Japanese circulation journal.

[123]  A. S. Gross,et al.  Influence of grapefruit juice on cisapride pharmacokinetics , 1999, Clinical pharmacology and therapeutics.

[124]  H. Crijns,et al.  QT lengthening and life-threatening arrhythmias associated with fexofenadine , 1999, The Lancet.

[125]  F. D. de Abajo,et al.  Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. , 1999, British journal of clinical pharmacology.

[126]  A. Camm,et al.  The current cardiac safety situation with antihistamines , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[127]  B. Drolet,et al.  Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. , 1999, The Journal of pharmacology and experimental therapeutics.

[128]  M. Langlois,et al.  Intestinal prokinesia by two esters of 4-amino-5-chloro-2- methoxybenzoic acid: involvement of 5-hydroxytryptamine-4 receptors and dissociation from cardiac effects in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[129]  Ronald Wilders,et al.  Contribution of L-type Ca2+current to electrical activity in sinoatrial nodal myocytes of rabbits. , 1999, American journal of physiology. Heart and circulatory physiology.

[130]  B. Drolet,et al.  Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. , 1999, The Journal of pharmacology and experimental therapeutics.

[131]  P. Bennett,et al.  Modulation of HERG potassium channels by extracellular magnesium and quinidine. , 1999, Journal of cardiovascular pharmacology.

[132]  D. Flockhart,et al.  Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6) , 1999, Clinical pharmacology and therapeutics.

[133]  N. El-Sherif,et al.  The Long QT Syndrome and Torsade De Pointes , 1999, Pacing and clinical electrophysiology : PACE.

[134]  A. Roach,et al.  Preclinical In Vitro Cardiac Electrophysiology , 1999, Drug safety.

[135]  J. Gras,et al.  Effects of H1 Antihistamines on Animal Models of QTc Prolongation , 1999, Drug safety.

[136]  R. Lemmens‐Gruber,et al.  Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[137]  V. Segarra,et al.  Computer-Assisted Comparison of the Structural and Electronic Dispositions of Ebastine and Terfenadine , 1999, Drug safety.

[138]  A. S. Davis.  The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods , 1998, Human & experimental toxicology.

[139]  A. Katchman,et al.  The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. , 1998, The Journal of pharmacology and experimental therapeutics.

[140]  T. Ogura,et al.  Inhibition of the rapid component of the delayed‐rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline , 1998, British journal of pharmacology.

[141]  W. Allan,et al.  The long-QT syndrome. , 2000, The New England journal of medicine.

[142]  K. Williams,et al.  Therapeutic drug monitoring: antiarrhythmic drugs. , 1998, British journal of clinical pharmacology.

[143]  M. Lazdunski,et al.  HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. , 1998, Molecular pharmacology.

[144]  R. Henthorn,et al.  Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. , 1998, American heart journal.

[145]  T. Yamamoto,et al.  Blockage by terfenadine of the adenosine triphosphate (ATP)-sensitive K+ current in rabbit ventricular myocytes. , 1998, The Journal of pharmacology and experimental therapeutics.

[146]  R. Bergstrom,et al.  A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism , 1998, European Journal of Clinical Pharmacology.

[147]  K. Hashimoto,et al.  Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. , 1998, Toxicology and applied pharmacology.

[148]  R. Sorelle.  Withdrawal of Posicor from market. , 1998, Circulation.

[149]  C. Tracy,et al.  QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. , 1998, Transplantation.

[150]  D. Rampe,et al.  The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. , 1998, The Journal of pharmacology and experimental therapeutics.

[151]  A. Brown,et al.  Blockade of HERG and Kv1.5 by ketoconazole. , 1998, The Journal of pharmacology and experimental therapeutics.

[152]  R. Woosley,et al.  "Conventional" antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. , 1998, Journal of cardiovascular pharmacology.

[153]  C. January,et al.  Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. , 1998, Molecular pharmacology.

[154]  E. Carmeliet,et al.  Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine , 1998, British journal of pharmacology.

[155]  C. Berul,et al.  Proarrhythmia associated with cisapride in children. , 1998, Pediatrics.

[156]  H. Hayakawa,et al.  Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous use. I. Effects of doses and infusion rate on blood pressure, heart rate and plasma histamine concentration. , 1998, Biological & pharmaceutical bulletin.

[157]  D. Roden.  Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.

[158]  A Varró,et al.  Intracellular calcium and electrical restitution in mammalian cardiac cells. , 1998, Acta physiologica Scandinavica.

[159]  C. Locke,et al.  Steady-State Pharmacokinetics and Electrocardiographic Pharmacodynamics of Clarithromycin and Loratadine after Individual or Concomitant Administration , 1998, Antimicrobial Agents and Chemotherapy.

[160]  R. Brooks,et al.  Azimilide dihydrochloride, a novel antiarrhythmic agent. , 1998, The American journal of cardiology.

[161]  J. Papp,et al.  Effect of disopyramide on potassium currents in rabbit ventricular myocytes , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[162]  C. Wurthmann,et al.  The Relationship Between Serum Concentration and Therapeutic Effect of Haloperidol in Patients with Acute Schizophrenia , 1998, Clinical pharmacokinetics.

[163]  A. Brady,et al.  Thioridazine, Diarrhoea and Torsades De Pointe , 1998, Journal of the Royal Society of Medicine.

[164]  B. Drolet,et al.  Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. , 1998, Circulation.

[165]  P. Lainée.  Electrocardiographic Effects of Mizolastine and Terfenadine in Conscious Dogs - Modifications induced by Ketoconazole Pretreatment - , 1998 .

[166]  L. Banken,et al.  Mibefradil pharmacokinetic and pharmacodynamic population analysis. , 1998, International journal of clinical pharmacology research.

[167]  A. Schömig,et al.  Frequency dependence in the action of the class III antiarrhythmic drug dofetilide is modulated by altering L-type calcium current and digitalis glucoside. , 1998, Journal of cardiovascular pharmacology.

[168]  Y. Ukai,et al.  Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. , 1998, General pharmacology.

[169]  M. Lazdunski,et al.  HERG and KvLQT 1 / IsK , the Cardiac K 1 Channels Involved in Long QT Syndromes , Are Targets for Calcium Channel Blockers , 1998 .

[170]  A. Bril,et al.  Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. , 1998, Cardiovascular research.

[171]  C. Funck-Brentano,et al.  Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. , 2003, British journal of clinical pharmacology.

[172]  J. Gurwitz.  Warfarin Therapy in the Nursing Home-Reply , 1997 .

[173]  C. de Zwaan,et al.  Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension. , 1997, Archives of internal medicine.

[174]  M. Rosen,et al.  Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: II. In vivo study. , 1997, Circulation.

[175]  J. Graybill,et al.  Therapeutic drug monitoring of systemic antifungal therapy. , 1997, The Journal of antimicrobial chemotherapy.

[176]  M. Q. Zhang.  Chemistry Underlying the Cardiotoxicity of Antihistamines , 1997 .

[177]  A. Brown,et al.  A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.

[178]  A. Moss,et al.  Electrocardiographic findings in patients with diphenhydramine overdose. , 1997, The American journal of cardiology.

[179]  Qiuming Gong,et al.  Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, American journal of physiology. Heart and circulatory physiology.

[180]  R. Clark,et al.  Clarithromycin-induced ventricular tachycardia. , 1997, Annals of emergency medicine.

[181]  Multiple modulations of action potential duration by different calcium channel blocking agents in guinea pig ventricular myocytes. , 1997, Journal of cardiovascular pharmacology.

[182]  M. Sekkarie,et al.  Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[183]  T. Costantino,et al.  A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. , 1997, Chest.

[184]  J. Czekalla,et al.  The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. , 1997, Pharmacopsychiatry.

[185]  A. Markham,et al.  Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. , 1997, Drugs.

[186]  K. Muraki,et al.  Effects of sematilide, a novel class III antiarrhythmic agent, on membrane currents in rabbit atrial myocytes. , 1997, European journal of pharmacology.

[187]  J. Levenson,et al.  Fatal Cardiac Event following Initiation of Risperidone Therapy , 1997, The Annals of pharmacotherapy.

[188]  G Duker,et al.  Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? , 1997, The Journal of pharmacology and experimental therapeutics.

[189]  K. Kamiya,et al.  Cellular electropharmacology of amiodarone. , 1997, Cardiovascular research.

[190]  R. Brooks,et al.  Pharmacology of Azimilide Dihydrochloride (NE-10064), A Class III Antiarrhythmic Agent , 1997 .

[191]  A. Casasoprana,et al.  Allongement de l'espace QT sous cisapride chez le nouveau-né et le nourrisson , 1997 .

[192]  C. Conde,et al.  Inhalatory pentamidine therapy and the duration of the QT interval in HIV-infected patients. , 1997, International journal of cardiology.

[193]  Y. Kii,et al.  Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. , 1997, Journal of cardiovascular pharmacology.

[194]  Y. Ukai,et al.  Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[195]  M. Morad,et al.  Suppression of mammalian K+ channel family by ebastine. , 1997, The Journal of pharmacology and experimental therapeutics.

[196]  W. Shimizu,et al.  Early Afterdepolarizationlike Activity in Patients with Class IA Induced Long QT Syndrome and Torsades de Pointes , 1997, Pacing and clinical electrophysiology : PACE.

[197]  C. Shapiro,et al.  Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. , 1997, Journal of clinical psychopharmacology.

[198]  J. Blanc,et al.  [Torsades de pointe with spiramycine and metiquazine therapy. Apropos of a case]. , 1997, Archives des maladies du coeur et des vaisseaux.

[199]  J. Cézard,et al.  [Long QT syndrome under cisapride in neonates and infants]. , 1997, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[200]  J. Johnson,et al.  Differences between blacks and whites in plasma protein binding of drugs , 1997, European Journal of Clinical Pharmacology.

[201]  D. Davis,et al.  Rate-dependent effects of sematilide on ventricular monophasic action potential duration and delayed rectifier K+ current in rabbits. , 1996, Journal of cardiovascular pharmacology.

[202]  Mark A. Wood,et al.  Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .

[203]  C. Funck-Brentano,et al.  Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. , 1996, Circulation.

[204]  T. Campbell,et al.  DIFFERENTIAL EFFECTS OF ANTIARRHYTHMIC AGENTS ON POST‐PAUSE REPOLARIZATION IN CARDIAC PURKINJE FIBRES , 1996, Clinical and experimental pharmacology & physiology.

[205]  J. Palacios,et al.  The role of ketoconazole in the QTc interval prolonging effects of H1‐antihistamines in a guinea‐pig model of arrhythmogenicity , 1996, British journal of pharmacology.

[206]  K. Muraki,et al.  Effects of sematilide, a novel class III antiarrhythmic agent, on delayed rectifier K+ current in guinea pig atrial myocytes. , 1996, Japanese journal of pharmacology.

[207]  A. Scialdone,et al.  [Sotalol, propafenone, and flecainide: compared multiparametric analysis of ventricular repolarization in subjects without organic cardiopathy]. , 1996, Cardiologia.

[208]  K. Hartigan-Go,et al.  Stereoselective cardiotoxic effects of terodiline , 1996, Clinical pharmacology and therapeutics.

[209]  C. Schmitt,et al.  Recording of transmembrane action potentials in chronic ischemic heart disease and dilated cardiomyopathy and the effects of the new class III antiarrhythmic agents D-sotalol and dofetilide. , 1996, Journal of cardiovascular pharmacology.

[210]  B. Dumotier,et al.  Cisapride‐induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres , 1996, British journal of pharmacology.

[211]  B. Darpö,et al.  Almokalant—A Selective Class III Antiarrhythmic Compound , 1996 .

[212]  A. Rialan,et al.  [Torsades de pointes in a patient under long-term maprotiline therapy. Apropos of a case]. , 1996, Annales de cardiologie et d'angeiologie.

[213]  M. Sanguinetti,et al.  Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. , 1996, Circulation research.

[214]  F. Ajayi,et al.  ECG pharmacodynamics and pharmacokinetics of halofantrine and mefloquine , 1996 .

[215]  R. Egan,et al.  Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. , 1996, Arzneimittel-Forschung.

[216]  R. Ruffolo,et al.  Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. , 1996, The Journal of pharmacology and experimental therapeutics.

[217]  L. Virág,et al.  The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. , 1996, Cardiovascular research.

[218]  C. Picado,et al.  A Review of its Pharmacological Properties and Clinical Efficacy in the Treatment of Allergic Disorders , 1996 .

[219]  R. Woosley,et al.  Cardiac actions of antihistamines. , 1996, Annual review of pharmacology and toxicology.

[220]  T. Ito,et al.  Effects of histamine H1 receptor antagonists on action potentials in guinea-pig isolated papillary muscles. , 1996, Archives internationales de pharmacodynamie et de therapie.

[221]  Y. Amitai,et al.  Chloral hydrate toxicity from oral and intravenous administration. , 1996, Journal of toxicology. Clinical toxicology.

[222]  T. Mori,et al.  Effect of terfenadine and KW-4679, a novel antiallergic compound, on action potential of guinea pig ventricular myocytes. , 1996, Japanese journal of pharmacology.

[223]  G. Hill,et al.  Diuretic-induced hypokalaemia inducing torsades de pointes , 1995, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[224]  J. Bauman,et al.  QT Interval Prolongation and Torsades de Pointes Due to Erythromycin Lactobionate , 1995, Pharmacotherapy.

[225]  T. Stern,et al.  The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. , 1995, Psychosomatics.

[226]  C. Nordin,et al.  Terfenadine Blocks Time‐Dependent Ca2+, Na+, and K+ Channels in Guinea Pig Ventricular Myocytes , 1995, Journal of cardiovascular pharmacology.

[227]  F. Colpaert,et al.  Investigation of the Mechanism by which Ketanserin Prolongs the Duration of the Cardiac Action Potential , 1995, Journal of cardiovascular pharmacology.

[228]  L. Carlsson,et al.  Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome. , 1995, Pharmacology & toxicology.

[229]  M. Boutjdir,et al.  Electrophysiologic Effects of Cocaine on Subendocardial Purkinje Fibers Surviving 1 Day of Myocardial Infarction , 1995, Journal of cardiovascular electrophysiology.

[230]  B. Dupuis,et al.  Electrophysiological and Arrhythmogenic Effects of the Histamine Type 1‐Receptor Antagonist Astemizole on Rabbit Purkinje Fibers: Clinical Relevance , 1995, Journal of cardiovascular pharmacology.

[231]  P. Daleau,et al.  Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. , 1995, Circulation.

[232]  D. Zipes,et al.  In Vivo and In Vitro Electrophysiologic Effects of Terodiline on Dog Myocardium , 1995, Journal of cardiovascular electrophysiology.

[233]  S. Krähenbühl,et al.  Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. , 1995, The American journal of the medical sciences.

[234]  J. Lynch,et al.  Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. , 1995, The Journal of pharmacology and experimental therapeutics.

[235]  A. Mbewu,et al.  Fluoxetine and ventricular torsade--is there a link? , 1995, International journal of cardiology.

[236]  D M Roden,et al.  Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. , 1995, Circulation.

[237]  J. Gabrielsson,et al.  Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites. , 1995, Pharmacology & toxicology.

[238]  J. Lynch,et al.  Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.

[239]  P. Adeleine,et al.  The hazards of chloroquine self prescription in west Africa. , 1995, Journal of toxicology. Clinical toxicology.

[240]  H. Just,et al.  Drug-Induced Torsade de Pointes , 1994, Drug safety.

[241]  C. Schmitt,et al.  Differential effects of D-sotalol on endocardial and epicardial action potentials of human ventricular myocardium in dilated cardiomyopathy. , 1994, Journal of cardiovascular pharmacology.

[242]  P. Doelken,et al.  Droperidol causes a dose-dependent prolongation of the QT interval. , 1994 .

[243]  P. Doelken,et al.  Droperidol Causes a Dose‐dependent Prolongation of the QT Interval , 1994, Anesthesia and analgesia.

[244]  H. Wiggers,et al.  Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs. , 1994, Cardiovascular research.

[245]  P. Sager,et al.  Effects of amiodarone, sematilide, and sotalol on QT dispersion. , 1994, The American journal of cardiology.

[246]  G. D. Johnston,et al.  The effect of probucol and vitamin E treatment on the oxidation of low‐density lipoprotein and forearm vascular responses in humans , 1994, European journal of clinical investigation.

[247]  M R Franz,et al.  New classification of moricizine and propafenone based on electrophysiologic and electrocardiographic data from isolated rabbit heart. , 1994, Journal of cardiovascular pharmacology.

[248]  M. Hiraoka,et al.  Rate-dependent effects of sematilide on action potential duration in isolated guinea pig ventricular myocytes. , 1994, The Journal of pharmacology and experimental therapeutics.

[249]  J. Brachmann,et al.  Differential Effects of the New Class III Agent Dofetilide on Potassium Currents in Guinea Pig Cardiomyocytes , 1994, Journal of cardiovascular pharmacology.

[250]  M. Franz,et al.  Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. , 1994, European heart journal.

[251]  B. Dupuis,et al.  In vitro electrophysiological detection of iatrogenic arrhythmogenicity , 1994, Fundamental & clinical pharmacology.

[252]  E. Prystowsky.  Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia , 1994, Clinical cardiology.

[253]  M. Biagetti,et al.  Chronic Versus Acute Effects of Amiodarone on the &OV0312;max-Conduction Velocity Relationship and on the Space Constant in Canine Myocardium , 1994, Journal of cardiovascular pharmacology.

[254]  K. Ohara,et al.  Effects of imipramine and amitriptyline on intraventricular conduction, effective refractory period, incidence of ventricular arrhythmias induced by programmed stimulation, and on electrocardiogram after myocardial infarction in dog. , 1994, Archives internationales de pharmacodynamie et de therapie.

[255]  J. Tamargo,et al.  Imipramine blocks rapidly activating and delays slowly activating K+ current activation in guinea pig ventricular myocytes. , 1994, Circulation research.

[256]  C. Pratt,et al.  Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. , 1994, The American journal of cardiology.

[257]  T. Inoue,et al.  QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine. , 1994, Cardiology.

[258]  P. Gillette,et al.  Developmental electrophysiology of encainide and its major metabolites on the Purkinje fiber action potential. , 1994, Biology of the neonate.

[259]  L. Carlsson,et al.  Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. , 1993, Cardiovascular research.

[260]  M. Ferrari,et al.  Pharmacokinetics and Electrophysiological Effects of Intravenous Ajmaline , 1993, Clinical pharmacokinetics.

[261]  R. Patterson,et al.  Intracoronary papaverine but not adenosine reduces regional ventricular function. , 1993, Cardiovascular research.

[262]  E. Carmeliet.  Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. , 1993, Circulation research.

[263]  S. Lavine,et al.  Effect of Ibutilide, a New Class III Agent, On Sustained Atrial Fibrillation in a Canine Model of Acute Ischemia and Myocardial Dysfunction Induced By Microembolization , 1993, Pacing and clinical electrophysiology : PACE.

[264]  D. Zipes,et al.  Electrophysiological Mechanisms in a Canine Model of Erythromycin‐Associated Long QT Syndrome , 1993, Circulation.

[265]  J. Brachmann,et al.  Effects of Prenylamine and AQ‐A 39 on Reentrant Ventricular Arrhythmias Induced During the Late Myocardial Infarction Period in Conscious Dogs , 1993, Journal of cardiovascular pharmacology.

[266]  T. Wenger,et al.  Terfenadine Alters Action Potentials in Isolated Canine Purkinje Fibers More Than Acrivastine , 1993, Journal of cardiovascular pharmacology.

[267]  P A Meredith,et al.  Pharmacodynamic modeling of the antihypertensive response to amlodipine , 1993, Clinical pharmacology and therapeutics.

[268]  B. Dupuis,et al.  Droperidol exerts dual effects on repolarization and induces early afterdepolarizations and triggered activity in rabbit Purkinje fibers. , 1993, The Journal of pharmacology and experimental therapeutics.

[269]  M. Iliou,et al.  [Torsades de pointes]. , 1993, Archives des maladies du coeur et des vaisseaux.

[270]  G Duker,et al.  Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. , 1993, Cardiovascular research.

[271]  R. Wesley,et al.  Ibutilide: enhanced defibrillation via plateau sodium current activation. , 1993, The American journal of physiology.

[272]  G. Kidwell,et al.  Effects of flecainide and D-sotalol on myocardial conduction and refractoriness: relation to antiarrhythmic and proarrhythmic drug effects. , 1993, Journal of cardiovascular pharmacology.

[273]  K. S. Lee,et al.  Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. , 1993, European journal of pharmacology.

[274]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[275]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[276]  D. Harron,et al.  Pharmacodynamics and Pharmacokinetics of the Class III Antiarrhythmic Agent Dofetilide (UK‐68,798) in Humans , 1993, Journal of cardiovascular pharmacology.

[277]  A. Stolfi,et al.  Electrophysiological Effects of High Cocaine Concentrations on Intact Canine Heart Evidence for Modulation by Both Heart Rate and Autonomic Nervous System , 1993, Circulation.

[278]  M. Sanguinetti,et al.  Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. , 1993, Circulation research.

[279]  E. Winer,et al.  High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. , 1992, Journal of the National Cancer Institute.

[280]  A. Turcant,et al.  [Torsades de pointes during sultopride poisoning]. , 1992, Journal de toxicologie clinique et experimentale.

[281]  D. Faulds,et al.  Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. , 1992, Drugs.

[282]  L. Carlsson,et al.  Electrophysiologic and Hemodynamic Effects of H 234/09 (Almokalant), Quinidine, and (+)-Sotalol in the Anesthetized Dog , 1992, Journal of cardiovascular pharmacology.

[283]  A. Bril,et al.  Comparative effects of a potassium channel blocking drug, UK-68,798, and a specific bradycardic agent, UL-FS 49, on exercise-induced ischemia in the dog: significance of diastolic time on ischemic cardiac function. , 1992, The Journal of pharmacology and experimental therapeutics.

[284]  E. Carmeliet.  Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. , 1992, The Journal of pharmacology and experimental therapeutics.

[285]  J. D. Coyle,et al.  Electrophysiologic Interactions of Procainamide and N‐Acetylprocainamide in Isolated Canine Cardiac Purkinje Fibers , 1992, Journal of cardiovascular pharmacology.

[286]  K. S. Lee.  Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. , 1992, The Journal of pharmacology and experimental therapeutics.

[287]  P. Brewster,et al.  The Effects of Cocaine on Cardiac Electrophysiology in Conscious, Unsedated Dogs , 1992, Journal of cardiovascular pharmacology.

[288]  R. N. Brogden,et al.  Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias. , 1992, Drugs.

[289]  B. Singh.  Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. , 1992, The American journal of cardiology.

[290]  J. Marsh,et al.  QT prolongation and Torsades de Pointes after administration of FK506. , 1992, Transplantation.

[291]  J. K. Gibson,et al.  Effects of Ibutilide on Spontaneous and Induced Ventricular Arrhythmias in 24‐Hour Canine Myocardial Infarction: A Comparative Study with Sotalol and Encainide , 1992, Journal of cardiovascular pharmacology.

[292]  D. Roden,et al.  Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. , 1992, The American journal of cardiology.

[293]  G. Lande,et al.  Effets arythmogènes du chlorydrate de sultopride : corrélation clinique et électrophysiologique cellulaire , 1992 .

[294]  M E Sullivan,et al.  An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. , 1992, Progress in medicinal chemistry.

[295]  E. Winslow,et al.  Comparative Frequency‐Dependent Effects of Three Class Ic Agents, Org 7797, F]ecanide, and Proprafenone, on ventricular Action Potential Duration , 1991, Journal of cardiovascular pharmacology.

[296]  G. Gintant,et al.  Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. , 1991, Circulation research.

[297]  D. Wyse,et al.  Propafenone‐Induced Torsade de Pointes: Cross‐Reactivity with Quinidine , 1991, Pacing and clinical electrophysiology : PACE.

[298]  J. Coutant,et al.  Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. , 1991, Journal of chromatography.

[299]  M. Ferrari,et al.  Ajmaline Test in a Patient with Chronic Renal Failure , 1991, Clinical pharmacokinetics.

[300]  M. Rosen,et al.  Use‐Dependent Actions and Effects on Transmembrane Action Potentials of Flecainide, Encainide, and Ethmozine in Canine Purkinje Fibers , 1991, Journal of cardiovascular pharmacology.

[301]  L. Chi,et al.  The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. , 1991, The Journal of pharmacology and experimental therapeutics.

[302]  R. B. Parker,et al.  Hemodynamic and Electrophysiological Actions of Cocaine: Effects of Sodium Bicarbonate as an Antidote in Dogs , 1991, Circulation.

[303]  T. Hedner,et al.  Clinical Pharmacokinetics of Ketanserin , 1991, Clinical pharmacokinetics.

[304]  A. Maseri,et al.  Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. , 1991, The New England journal of medicine.

[305]  H. De Geest,et al.  Torsades de pointes after intracoronary papaverine. , 1991, European heart journal.

[306]  J. Henry,et al.  Life-Threatening Ventricular Arrhythmia (Torsades de Pointes) after Haloperidol Overdose , 1991, Human & experimental toxicology.

[307]  L. Storstein,et al.  Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration. An evaluation of acute cardiotoxicity by continuous 24-hour Holter monitoring. , 1991, Acta oncologica.

[308]  S. Port,et al.  Coronary vasodilator reserve. Comparison of the effects of papaverine and adenosine on coronary flow, ventricular function, and myocardial metabolism. , 1991, Circulation.

[309]  E. Winslow,et al.  Effects of Amiodarone on Cardiac Electrophysiology and Inducibility of Arrhythmias in Chronically Infarcted Dogs: Late Arrhythmias, Haemodynamics, and Sympatholytic Actions , 1990, Journal of cardiovascular pharmacology.

[310]  G. Kerr,et al.  Torsade de pointes associated with perhexiline maleate therapy. , 1990, Australian and New Zealand journal of medicine.

[311]  W. Kübler,et al.  Electrophysiologic effects of bepridil in patients with refractory ventricular tachycardia assessed by programmed electrical stimulation , 1990, Clinical cardiology.

[312]  H. Nakaya,et al.  Effects of N-acetylprocainamide and sotalol on ion currents in isolated guinea-pig ventricular myocytes. , 1990, European journal of pharmacology.

[313]  P. Lieberman,et al.  The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. , 1990, The Journal of allergy and clinical immunology.

[314]  D. Schwartzman,et al.  Cocaine-induced torsades de pointes in a patient with the idiopathic long QT syndrome. , 1990, American heart journal.

[315]  Comparability of the Electrophysiologic Responses and Plasma and Myocardial Tissue Concentrations of Sotalol and its d Stereoisomer in the Dog , 1990, Journal of cardiovascular pharmacology.

[316]  M. Morad,et al.  Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[317]  M. Kern,et al.  Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve. , 1990, Catheterization and cardiovascular diagnosis.

[318]  Lack of Triggered Automaticity Despite Repolarization Abnormalities due to Bepridil and Lidoflazine , 1990, Pacing and clinical electrophysiology : PACE.

[319]  S. Hohnloser,et al.  Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group. , 1990, Clinical physiology and biochemistry.

[320]  D Tzivoni,et al.  Torsade de pointes. , 1989, American heart journal.

[321]  A. Jain,et al.  Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine. , 1989, Catheterization and cardiovascular diagnosis.

[322]  N. Edvardsson,et al.  Torsade de pointes tachycardias induced by overdosage of zimeldine. , 1989, Journal of cardiovascular pharmacology.

[323]  M. Rosen,et al.  Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. , 1989, The Journal of pharmacology and experimental therapeutics.

[324]  S. Lundgren,et al.  Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. , 1989, Cancer research.

[325]  S. Hohnloser,et al.  Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. , 1989, The American journal of cardiology.

[326]  H. Greene.  The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. , 1989, Progress in cardiovascular diseases.

[327]  B. Sadler,et al.  Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[328]  M. E. Veronese,et al.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. , 1988, British journal of clinical pharmacology.

[329]  J. Palussiere,et al.  [QT prolongation and induction of torsades de pointe by flecainide. Apropos of a case]. , 1988, Archives des maladies du coeur et des vaisseaux.

[330]  A. Pelech,et al.  ASTEMIZOLE-INDUCED TORSADE DE POINTES , 1988, The Lancet.

[331]  D. Noble,et al.  The effects of prenylamine on single ventricular myocytes of guinea‐pig , 1988, British journal of pharmacology.

[332]  I. Ovsyshcher.  Torsades de pointes. , 1988, American heart journal.

[333]  J. Tamargo,et al.  Comparison of six new antidepressants on isolated rat atria. , 1988, Arzneimittel-Forschung.

[334]  R. Woestenborghs,et al.  Excretion and biotransformation of cisapride in dogs and humans after oral administration. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[335]  K. Nademanee,et al.  Control of Cardiac Arrhythmias by Calcium Antagonism a , 1988, Annals of the New York Academy of Sciences.

[336]  Y. Kurata,et al.  Electrophysiological effects of maprotiline, a tetracyclic antidepressant agent, on isolated cardiac preparations. , 1988, Journal of cardiovascular pharmacology.

[337]  D. Roden,et al.  Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. , 1987, The Journal of pharmacology and experimental therapeutics.

[338]  T. Campbell,et al.  Resting, and rate‐dependent depression of of guinea‐pig ventricular action potentials by amiodarone and desethylamiodarone , 1987, British journal of pharmacology.

[339]  T. Cooper,et al.  Cardiovascular effects of doxepin in cardiac patients with ventricular arrhythmias , 1987, Clinical pharmacology and therapeutics.

[340]  M. Rosengarten,et al.  Torsade de pointes ventricular tachycardia in a hypothyroid patient treated with propafenone. , 1987, The Canadian journal of cardiology.

[341]  A. Rocchini,et al.  Quinidine syncope in children. , 1987, Journal of the American College of Cardiology.

[342]  J. A. Gomes,et al.  ECG changes during haloperidol and pimozide treatment of Tourette's disorder. , 1987, The American journal of psychiatry.

[343]  M. Yokota,et al.  Non-linear pharmacokinetics of aprindine hydrochloride in oral administration. , 1987, Arzneimittel-Forschung.

[344]  S. Laxminarayan,et al.  Characterization of the class I antiarrhythmic activity of cibenzoline succinate in guinea pig papillary muscle. , 1987, The Journal of pharmacology and experimental therapeutics.

[345]  K. Hashimoto,et al.  Effect of cibenzoline, a class I antiarrhythmic drug, on action potential in canine ventricular muscle. , 1987, Japanese journal of pharmacology.

[346]  F. Casazza,et al.  [Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case]. , 1986, Giornale italiano di cardiologia.

[347]  R. Marshall,et al.  Comparative Electrophysiological Effects of Disopyramide and Bepridil on Rabbit Atrial, Papillary, and Purkinje Tissue: Modification by Reduced Extracellular Potassium , 1986, Journal of cardiovascular pharmacology.

[348]  D. Roden,et al.  Disposition kinetics of encainide and metabolites. , 1986, The American journal of cardiology.

[349]  P. Touboul,et al.  Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration. , 1986, American heart journal.

[350]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[351]  B. Singh,et al.  Effects of bepridil on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. , 1986, American heart journal.

[352]  C. Raehl,et al.  Drug-induced torsade de pointes. , 1985, Clinical pharmacy.

[353]  D. Paton,et al.  Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines) , 1985, Clinical pharmacokinetics.

[354]  R. Man,et al.  Electrophysiological actions of flecainide in normal and infarcted canine Purkinje fibers. , 1985, European journal of pharmacology.

[355]  E. Carmeliet.  Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. , 1985, The Journal of pharmacology and experimental therapeutics.

[356]  L. D. Davis,et al.  Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. , 1985, Journal of the American College of Cardiology.

[357]  F. Aoki,et al.  Prophylactic amantadine dose and plasma concentration—effect relationships in healthy adults , 1985, Clinical pharmacology and therapeutics.

[358]  E. Davison.  Amitriptyline-induced Torsade de Pointes. Successful therapy with atrial pacing. , 1985, Journal of electrocardiology.

[359]  C. S. Nath,et al.  Ajmaline-induced torsade de pointes. , 1985, Cardiology.

[360]  R. Walls,et al.  QT interval prolongation. , 1985, The Journal of emergency medicine.

[361]  R. Hamlin,et al.  Effects of disopyramide on the electrocardiogram and ventricular function in the unanesthetized dog. , 1984, Journal of veterinary pharmacology and therapeutics.

[362]  J. Hill,et al.  Effects of bepridil on the resting electrocardiogram. , 1984, International journal of cardiology.

[363]  J. Bauman,et al.  Fatal Maprotiline Intoxication , 1984, Drug intelligence & clinical pharmacy.

[364]  J. Young,et al.  Torsade de Pointe. Malignant cardiac arrhythmia induced by amantadine poisoning. , 1984, The American journal of medicine.

[365]  J. Brachmann,et al.  Actions of disopyramide on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs during the late post-myocardial infarction phase. , 1984, The American journal of cardiology.

[366]  R. Man,et al.  The interaction of cycle length with the electrophysiological effect of lidocaine, tocainide and verapamil on canine Purkinje fibers. , 1984, European journal of pharmacology.

[367]  Edward G. Ablnader.  Q-T prolongation and torsades de pointes ventricular tachycardia produced by maprotiline. , 1984 .

[368]  A. Keren,et al.  Magnesium therapy for torsades de pointes. , 1984, The American journal of cardiology.

[369]  K. Lasseter,et al.  Steady‐State Pharmacokinetics of Nitrendipine in Hepatic Insufficiency , 1984, Journal of cardiovascular pharmacology.

[370]  W. Kirch,et al.  Drug Interactions with Nitrendipine , 1984, Journal of cardiovascular pharmacology.

[371]  J. Hampton,et al.  Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial. , 1983, European heart journal.

[372]  B. Lucchesi,et al.  Ventricular fibrillation in a conscious canine preparation of sudden coronary death--prevention by short- and long-term amiodarone administration. , 1983, Circulation.

[373]  H. A. Grayson,et al.  Nifedipine and torsades de pointes. , 1983, Annals of internal medicine.

[374]  T. Campbell.  Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. , 1983, Cardiovascular research.

[375]  H. Herrmann,et al.  Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. , 1983, The American journal of cardiology.

[376]  K. Kane,et al.  Electrophysiological Effects of Lidocaine, l-Chlorpheniramine, and Bepridil on Rabbit Sinus Node Pacemaker Cells , 1983, Journal of cardiovascular pharmacology.

[377]  R. Veith,et al.  ECG Effects of Comparable Plasma Concentrations of Desipramine and Amitriptyline , 1982, Journal of clinical psychopharmacology.

[378]  Lee Jm,et al.  Methods of collecting data. , 1982 .

[379]  S. Swiryn,et al.  Doxepin Induced Torsade De Pointes , 1982, Pacing and clinical electrophysiology : PACE.

[380]  D. Krikler,et al.  Torsade de pointes and nifedipine. , 1982, Annals of internal medicine.

[381]  H. A. Grayson,et al.  Torsades de pointes and nifedipine. , 1982, Annals of internal medicine.

[382]  K. Rosen,et al.  Aprindine-induced polymorphous ventricular tachycardia. , 1982, The American journal of cardiology.

[383]  E. Prystowsky,et al.  Electrophysiology of oral encainide. , 1982, The American journal of cardiology.

[384]  J. Millar,et al.  EFFECTS ON RABBIT NODAL, ATRIAL, VENTRICULAR AND PURKINJE CELL POTENTIALS OF A NEW ANTIARRHYTHMIC DRUG, CIBENZOLINE, WHICH PROTECTS AGAINST ACTION POTENTIAL SHORTENING IN HYPOXIA , 1982, British journal of pharmacology.

[385]  U. Borchard,et al.  Effect of Flecainide on Action Potentials and Alternating Current‐Induced Arrhythmias in Mammalian Myocardium , 1982, Journal of cardiovascular pharmacology.

[386]  W. Muir,et al.  Effects of Tricyclic Antidepressant Drugs on the Electrophysiological Properties of Dog Purkinje Fibers , 1982, Journal of cardiovascular pharmacology.

[387]  D. Harrison,et al.  Electrophysiologic evaluation of encainide with use of monophasic action potential recording. , 1981, The American journal of cardiology.

[388]  G. Cocco,et al.  Torsades de pointes as a manifestation of mexiletine toxicity. , 1980, American heart journal.

[389]  D. Chamberlain,et al.  The effect of prenylamine on the QT interval of the resting electrocardiogram in patients with angina pectoris. , 1980, Postgraduate medical journal.

[390]  P. McDonald,et al.  Intersubject and dose-related variability after intravenous administration of erythromycin. , 1980, British journal of clinical pharmacology.

[391]  B. A.,et al.  Sudden Death , 1855, Developments in Cardiovascular Medicine.

[392]  J. .. Abildskov.  The prolonged QT interval. , 1979, Annual review of medicine.

[393]  P. Poole‐Wilson,et al.  Acute effects of diuretics on potassium exchange, mechanical function and the action potential in rabbit myocardium. , 1978, Clinical science and molecular medicine. Supplement.

[394]  P. Jatlow,et al.  Oral cocaine: plasma concentrations and central effects. , 1978, Science.

[395]  B. Kennelly.  Comparison of lidoflazine and quindine in prophylactic treatment of arrhythmias. , 1977, British heart journal.

[396]  D. Krikler,et al.  Torsade De Pointes, an atypical ventricular tachycardia. , 1976, British heart journal.

[397]  D. Mason,et al.  Electrophysiologic properties of perhexiline , 1975, Clinical pharmacology and therapeutics.

[398]  G. Pastelín,et al.  The effects of ajmaline in experimental and clinical arrhythmias and their relation to some electrophysiological parameters of the heart. , 1975, The Journal of pharmacology and experimental therapeutics.

[399]  H Herken,et al.  Drug Safety , 1980, Medizinische Klinik.

[400]  D. Garcia-Dorado,et al.  Cardiovascular Research , 1966 .

[401]  F Dessertenne,et al.  [Ventricular tachycardia with 2 variable opposing foci]. , 1966, Archives des maladies du coeur et des vaisseaux.

[402]  J. Kosek,et al.  SUDDEN DEATH DURING TREATMENT WITH PHENOTHIAZINE DERIVATIVES. , 1965, JAMA.

[403]  Bennie Zak,et al.  Progress in Medicinal Chemistry , 1964 .

[404]  R. C. Macridis.  A review , 1963 .

[405]  M. Eberhard,et al.  The genus Mansonella (syn. Tetrapetalonema): a new classification. , 1984, Annales de parasitologie humaine et comparee.

[406]  Martindale.,et al.  THE EXTRA PHARMACOPOEIA , 1937 .

[407]  J A Macwilliam,et al.  SOME APPLICATIONS OF PHYSIOLOGY TO MEDICINE , 1923, British medical journal.

[408]  Committee for proprietary medicinal products (CPMP) points to consider on adjustment for baseline covariates , 2022 .